Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi (lecanemab-irmb) after the US Food and Drug Administration (FDA) ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center identified a cocktail of three different drugs that can be used to generate more robust ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Biologics ...

Bristol Myers Squibb CEO Chris Boerner described Cobenefy, a new drug to treat schizophrenia and may also help with bipolar ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center have identified a ...

A THOROUGH investigation looms over the Philippine National Police (PNP) confiscation of illegal drugs since 2016 ahead of ...

Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

The sleep aid Ambien could be allowing toxic proteins to pollute the brain, potentially increasing a person’s risk of ...